BioCatalyst

Ixo-vec, Aflibercept — catalyst calendar

1 verified catalyst event(s) referencing Ixo-vec, Aflibercept, each linked to its official source. Verified as of 2026-09-20.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-12-22
in 3mo
ESTIMATED
 READOUT
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants
Phase 3 · Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
 Adverum Biotechnologies, Inc. Ixo-vec, Aflibercept ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.